Simulations Plus, Inc. (NASDAQ:SLP) Files An 8-K Submission of Matters to a Vote of Security Holders

Simulations Plus, Inc. (NASDAQ:SLP) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders:

On February 26, 2018, Simulations Plus, Inc., a California corporation (the "Company"), held its annual meeting of shareholders (the “Annual Meeting”). The following proposals were submitted to a vote of security holders at the meeting.

1. Proposal No. 1: To elect to the Board of Directors five (5) directors, to serve until the next Annual Meeting of Shareholders of the Company or until their successors are elected and qualified, subject to prior death, resignation or removal.

2. Proposal No. 2: To ratify the appointment of Rose, Snyder and Jacobs as our independent registered public accounting firm for the Company for the fiscal year ending August 31, 2018.

The above proposals were approved and the results of the balloting at the meeting are summarized in the following tables.

Proposal

Votes For

Votes Against Votes Abstaining

Votes

Withheld

Broker-Non votes

Not Voted

Total

(a)

(1) Walter Woltosz 11,319,140 43,299 127,661 4,312,301 5,989 15,808,390
(1) Dr. Thaddeus H. Grasela 11,367,408 43,299 79,393 4,312,301 5,989 15,808,390
(1) Dr. John K. Paglia 11,332,156 43,299 114,645 4,312,301 5,989 15,808,390
(1) Dr. David Ralph 10,954,308 43,299 492,493 4,312,301 5,989 15,808,390
(1) Dr. Daniel Weiner 11,398,961 43,299 47,840 4,312,301 5,989 15,808,390
(2) Appointment of Rose, Snyder and Jacobs LLP 15,519,423 13,752 275,215 15,808,390

(a) Total Proxy Shares on record date on December 29, 2017, 17,287,652 out of which 15,808,390 shares were reported.

On February 26, 2018, the Company held its annual meeting of shareholders. A copy of the PowerPoint presentation for the meeting is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This report on Form 8-K (the "Report"), including the disclosures set forth herein, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms "anticipates," "expects," "estimates," "believes" and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements.

Forward-looking statements in this Report or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission (the "Commission"), reports to the stockholders of Simulations Plus, Inc., a California corporation (the "Company" or "us," "our" or "we") and other publicly available statements issued or released by us involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management's best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Commission, each of which could adversely affect our business and the accuracy of the forward-looking statements contained herein. Our actual results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements.

Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.1 PowerPoint Presentation on February 26, 2018.


SIMULATIONS PLUS INC Exhibit
EX-99.1 2 simulations_8k-ex9901.htm POWERPOINT PRESENTATION Exhibit 99.1   (NASDAQ:SLP) Annual Shareholders’ Meeting February 26,…
To view the full exhibit click here

About Simulations Plus, Inc. (NASDAQ:SLP)

Simulations Plus, Inc. (Simulations Plus) develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour. MedChem Designer includes a small set of ADMET Predictor property predictions, allowing the chemist to modify molecular structures. MedChem Studio is a tool for medicinal and computational chemists for both data mining and for designing new drug-like molecules. DDDPlus simulates in-vitro laboratory experiments used to measure the rate of dissolution of the drug. GastroPlus simulates the absorption, pharmacokinetics, and pharmacodynamics of drugs.

An ad to help with our costs